Guanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD)
Floyd R Sallee1, Katherine Eaton
1University of Cincinnati, Department of Psychiatry, OH 45219, USA. floyd.sallee@uc.edu
Expert Opinion on Pharmacotherapy
|September 14, 2010
Summary
Guanfacine extended-release (GXR) effectively treats attention deficit/hyperactivity disorder (ADHD) in children and adolescents. This non-stimulant medication is well-tolerated and may help with oppositional symptoms, offering a new option in ADHD management.
Area of Science:
- Pharmacology and Therapeutics
- Neuroscience
- Pediatric Medicine
Background:
- Attention deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder.
- Guanfacine extended-release (GXR) is a novel non-stimulant α(2A)-adrenoceptor agonist for ADHD treatment.
- GXR offers an alternative to traditional psychostimulants and atomoxetine in a competitive ADHD market.
Purpose of the Study:
- To review the pharmacodynamics, pharmacokinetics, clinical efficacy, and safety of GXR.
- To evaluate GXR's role in managing ADHD, including oppositional symptoms and combination therapy.
- To inform clinicians about GXR's place in the ADHD treatment landscape.
Main Methods:
- Comprehensive literature review of MEDLINE and EMBASE (1980-2010).
- Analysis of two pivotal controlled trials and associated 24-month safety studies.
- Inclusion of studies on GXR for ADHD with oppositional symptoms and in psychostimulant non-responders.
Main Results:
- GXR demonstrates a potentially novel mechanism of action complementing existing ADHD therapies.
- Evidence supports GXR as a well-tolerated and effective treatment for pediatric ADHD.
- GXR showed efficacy in reducing oppositional symptoms and was generally safe, with mild, transient decreases in blood pressure and heart rate.
Conclusions:
- GXR is a safe and effective non-stimulant option for ADHD treatment in children and adolescents.
- The drug's profile suggests utility in specific ADHD presentations, including those with oppositional symptoms.
- This review provides insights for integrating GXR into comprehensive ADHD management strategies.
More Related Videos
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...